Document is current
Any future updates will be listed below
-
Authors
Witkiewicz, Agnieszka K.
Wang, Jianxin https://orcid.org/0000-0002-0998-4996
Schultz, Emily https://orcid.org/0000-0001-8591-0609
O’Connor, Thomas N.
O’Connor, Tracey
Levine, Ellis
Knudsen, Erik S. https://orcid.org/0000-0002-5130-5969
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA247362, CA247362-S1, CA247362, CA247362-S1)
Roswell Park Alliance Foundation, Roswell Park Cancer Institute
- License Information
-
More Information
Article History
Received: 13 August 2024
Revised: 6 January 2025
Accepted: 10 February 2025
First Online: 26 February 2025
Competing interests
: ESK and AKW have sponsored research funded by Blueprint Medicine and Bristol Myers Squibb, in addition to funding received from the Roswell Park Alliance Foundation and National Cancer Institute. ESK is also a member of the Cancer Cell Cycle-LLC consulting enterprise. All other authors have no competing interests to declare.
: All patient data collection, protocols, and methods of this specific study were conducted in accordance with the principles outlined in the Declaration of Helsinki. All methods used in this study were approved by the RPCCC Institutional Review Board under the Roswell Park Remnant Tissue Protocol and through written informed consent received from all participating patients under clinical trial .
